Seminar - “Heart-on-a-plate for Drug Discovery and Disease Modeling” by Milica Radisic, Department of Chemical Engineering & Applied Chemistry, University of Toronto
ABSTRACT: The current drug development process is both very slow (15 year average) and costly ($1.5B/drug average). Despite this hefty investment, inefficiencies in the drug screening process routinely result in the withdrawal of drugs from the market due to serious toxicities and adverse cardiovascular effects. Safety screen assessments performed on cell cultures and animal models do not always correlate with clinical risk.
Paul Chen, a PhD candidate supervised by Prof. Frank Gu, has been awarded a prestigious

